GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

BL/ - The names of the most important Chief Sustainability Officers of Europe were announced at the Futur/io C ...

As the percentage of the global population over 65 continues to increase, the popularity of anti-aging stocks is rising in ...

We anticipate that their industry-leading approach will accelerate the discovery of new molecules against high value GSK targets with ... discovery firms are also building their own in-house ...

Building this trust among employees involves ... is aiming to “do the right thing” for wider society. With the new goals, GSK aims to have a net zero impact on climate and a net positive ...

Barbara Salami is the VP of Digital for Commercial at Moderna where she is leads digital transformation for Moderna’s new ...

The China-based cancer drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.

Cancer is now the second leading cause of death worldwide, and rates are climbing-especially in younger adults. Breast, ...

Kassa and others said Big Pharma continues to invest even as private equity funds have pulled back. He noted ...

Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule ...

Anixa Biosciences CEO Amit Kumar discusses the biotech’s plans for advancing a breast cancer vaccine in 2025. The cancer ...

Natural capital went mainstream in 2024, with biodiversity bonds hitting new highs and record shareholder resolutions on ...